Modality
Bispecific Ab
MOA
MDM2i
Target
B7-H3
Pathway
STING
Cervical Ca
Development Pipeline
Preclinical
~Oct 2015
→ ~Jan 2017
Phase 1
~Apr 2017
→ ~Jul 2018
Phase 2
Oct 2018
→ Dec 2027
Phase 2Current
NCT06825748
1,123 pts·Cervical Ca
2018-10→2027-12·Terminated
1,123 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-12-071.7y awayPh3 Readout· Cervical Ca
Trial Timeline
Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q4
P2/3
Termina…
Catalysts
Ph3 Readout
2027-12-07 · 1.7y away
Cervical Ca
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06825748 | Phase 2/3 | Cervical Ca | Terminated | 1123 | FEV1 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-4358 | Eli Lilly | Phase 3 | B7-H3 | |
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| Ceviglumide | Roche | NDA/BLA | B7-H3 | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-8628 | Sanofi | NDA/BLA | B7-H3 | |
| SNY-9073 | Sanofi | Phase 2 | B7-H3 | |
| NVO-7840 | Novo Nordisk | Phase 2/3 | B7-H3 | |
| NVO-7872 | Novo Nordisk | NDA/BLA | B7-H3 | |
| DSN-5254 | Daiichi Sankyo | Phase 1 | B7-H3 |